Machinery & EquipmentTop Companies
Machinery & Equipment

Top Apheresis Equipment Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Machinery & Equipment

Published

Jan 2026

Share:

Machinery & Equipment

Top Apheresis Equipment Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size (US$)
2.78 Billion
2026 Forecast (US$)
2.99 Billion
2032 Forecast (US$)
4.61 Billion
CAGR (2025-2032)
7.40%

Summary

The global Apheresis Equipment market is entering a robust expansion phase, driven by rising plasma therapies, transfusion safety norms, and automation needs. Leading Apheresis Equipment market companies consolidate share through integrated platforms, service contracts, and digital upgrades, supporting growth from US$ 2.78 Billion in 2025 to US$ 4.61 Billion by 2032 at a 7.40% CAGR.

2025 Revenue of Top Apheresis Equipment Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

Rankings of Apheresis Equipment market companies are based on a composite score integrating quantitative and qualitative criteria. Core inputs include estimated 2025 apheresis equipment revenue, three-year growth trajectory, and installed base across hospitals, blood centers, and plasma-collection networks. We also assess technology differentiation such as automation level, cross-therapy versatility, software integration, and connectivity features. Portfolio breadth, including disposables and services, and global service coverage with uptime guarantees materially influence scores. Additional weight is assigned to the ability to win multi-year framework agreements, execute long-term maintenance contracts, and support regulatory compliance in highly scrutinized markets. Strategic moves—M&A, partnerships, digital health initiatives, and clinical evidence generation—are reviewed to gauge future competitiveness. Each factor is normalized into a 100-point model, peer-benchmarked, and synthesized into a final ranking that reflects both current scale and forward-looking strength.

Top 10 Companies in Apheresis Equipment

1
Fresenius SE & Co. KGaA (Fresenius Kabi)
Aurora, COM.TEC, Amicus, ATS
Therapeutic apheresis devices, plasma collection systems, disposables, service contracts
Bad Homburg, Germany
Europe, North America, Latin America, Middle East
Expanded plasma-collection partnerships in U.S., launched software upgrades for connected apheresis fleet, strengthened service presence in Asia-Pacific
≈ 29.00%
US$ 820.00 Million
2
Haemonetics Corporation
NexSys PCS, MCS+, Cell Saver Elite
Plasma collection systems, blood center automation, therapeutic apheresis, software
Boston, USA
North America, Europe, China
Accelerated deployment of NexSys platforms, advanced donor management analytics, and digital connectivity with large plasma-collection networks
≈ 25.00%
US$ 700.00 Million
3
Terumo BCT, Inc.
Spectra Optia, COBE Spectra, Quantum Cell Expansion
Therapeutic apheresis, cell processing, blood component separation, disposables
Lakewood, USA (Terumo Corporation, Japan)
North America, Japan, Europe, emerging Asia
Expanded installed base in oncology centers, integrated cell-therapy workflows, and invested in software-based clinical decision support
≈ 19.00%
US$ 540.00 Million
4
Asahi Kasei Medical Co., Ltd.
Plasauto, Aphereis series, selective adsorption columns
Therapeutic apheresis columns, blood purification, filters, select hardware
Tokyo, Japan
Japan, wider Asia, growing presence in Europe
Strengthened immunology and neurology indications, broadened distribution partnerships in Europe, and advanced R&D in selective adsorption
≈ 7.50%
US$ 210.00 Million
5
B. Braun Melsungen AG
Diapact CRRT systems with apheresis modules
Therapeutic plasma exchange, dialysis-related apheresis, disposables
Melsungen, Germany
Europe, Middle East, Latin America
Integrated apheresis options into renal portfolios, enhanced training programs, and pursued bundled contracts with hospital groups
≈ 4.30%
US$ 120.00 Million
6
Kawasumi Laboratories Inc.
Kawasumi apheresis kits, blood collection sets
Apheresis disposables, blood bags, specialty kits
Tokyo, Japan
Japan, Asia, selected U.S. and European accounts
Focused on OEM partnerships, customized disposables, and cost-efficient offerings for high-volume plasma centers
≈ 2.90%
US$ 80.00 Million
7
Nikkiso Co., Ltd.
Nikkiso apheresis modules, dialysis platforms
Blood purification, therapeutic apheresis modules integrated with dialysis
Tokyo, Japan
Japan, Asia-Pacific, Middle East
Piloted combined renal and apheresis therapies, strengthened clinical collaborations, and expanded into high-acuity ICUs
≈ 2.20%
US$ 60.00 Million
8
Kaneka Corporation
Liposorber, Immusorba series
Lipoprotein apheresis, immunoadsorption systems, columns
Osaka, Japan
Japan, Europe, selected North American centers
Expanded indications in cardiology and autoimmune diseases, invested in clinical data, and enhanced training for specialized centers
≈ 2.00%
US$ 55.00 Million
9
Macopharma SA
Macopharma apheresis kits, platelet collection sets
Apheresis disposables, blood bags, leukoreduction filters
Tourcoing, France
Europe, Middle East, Africa
Enhanced value-based tenders, broadened OEM collaborations, and optimized supply chain resilience for blood centers
≈ 1.60%
US$ 45.00 Million
10
Cerus Corporation
INTERCEPT Blood System
Pathogen reduction for blood components, related apheresis integrations
Concord, USA
North America, Europe, selected Asia-Pacific markets
Integrated pathogen reduction with apheresis workflows, secured agreements with national blood services, and advanced clinical evidence generation
≈ 1.40%
US$ 40.00 Million

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Fresenius SE & Co. KGaA (Fresenius Kabi)

Global healthcare group and leading supplier of apheresis systems, disposables, and services for plasma collection and therapeutic applications.

Key Financials: 2025 Apheresis Equipment revenue US$ 820.00 Million; estimated segment CAGR 7.80%.
Flagship Products: Aurora, COM.TEC, Amicus, ATS
2025-2026 Actions: Expanded software-enabled fleet management, deepened partnerships with large plasma-collection organizations, and invested in training academies worldwide.
Three-line SWOT: Scale and full-solution portfolio across hardware, disposables, and service; Complex organization may slow innovation cycles; Opportunity—growing global plasma demand and hospital outsourcing of maintenance.
Notable Customers: CSL Plasma, Grifols plasma centers, major university hospitals in Europe and North America
2

Haemonetics Corporation

Specialized blood-management and apheresis technology company focused on plasma, whole-blood automation, and perioperative blood conservation.

Key Financials: 2025 Apheresis Equipment revenue US$ 700.00 Million; operating margin 18.50%.
Flagship Products: NexSys PCS, MCS+, Cell Saver Elite
2025-2026 Actions: Rolled out connected donor management platforms, optimized plasma-center throughput, and pursued software-driven differentiation for key accounts.
Three-line SWOT: Strong software and analytics capabilities; High dependence on plasma segment dynamics; Opportunity—expansion into emerging markets and diversification into hospital-based therapeutic procedures.
Notable Customers: Takeda BioLife, Octapharma plasma centers, leading regional blood centers in the U.S. and Europe
3

Terumo BCT, Inc.

Global leader in therapeutic apheresis and cell processing, serving oncology, neurology, and cell-therapy centers with integrated platforms.

Key Financials: 2025 Apheresis Equipment revenue US$ 540.00 Million; R&D spend around 9.50% of revenue.
Flagship Products: Spectra Optia, COBE Spectra, Quantum Cell Expansion
2025-2026 Actions: Expanded clinical programs in cellular immunotherapy, integrated data analytics into devices, and increased presence in specialty care centers.
Three-line SWOT: Broad modality coverage and strong clinical reputation; Higher system complexity requires intensive training; Opportunity—rapid growth of cell and gene therapies demanding advanced apheresis capabilities.
Notable Customers: MD Anderson Cancer Center, major Japanese university hospitals, leading European transplant centers
4

Asahi Kasei Medical Co., Ltd.

Diversified medical business with strong specialization in blood purification and selective therapeutic apheresis technologies.

Key Financials: 2025 Apheresis Equipment revenue US$ 210.00 Million; estimated operating margin 16.20%.
Flagship Products: Plasauto, Aphereis series, selective adsorption columns
2025-2026 Actions: Strengthened neurology and autoimmune indications, widened distributor networks, and advanced clinical trials for novel adsorption applications.
Three-line SWOT: Strong expertise in hemoadsorption and selective therapies; Comparatively limited standalone device portfolio; Opportunity—rising prevalence of autoimmune and inflammatory diseases needing targeted apheresis solutions.
Notable Customers: Japanese tertiary-care hospitals, European specialty clinics, regional distributors in Asia-Pacific
5

B. Braun Melsungen AG

Large medtech player integrating apheresis options into renal and critical-care platforms for hospitals worldwide.

Key Financials: 2025 Apheresis Equipment revenue US$ 120.00 Million; segment growth about 6.80% annually.
Flagship Products: Diapact CRRT systems with apheresis modules
2025-2026 Actions: Bundled CRRT and apheresis offerings in tenders, enhanced clinician training, and expanded service teams in Europe and Middle East.
Three-line SWOT: Strong hospital relationships and bundled critical-care solutions; Apheresis is a smaller non-core business; Opportunity—synergies by combining renal replacement and plasma exchange in intensive care units.
Notable Customers: Large European hospital groups, Middle Eastern government hospitals, Latin American private chains
6

Kawasumi Laboratories Inc.

Japanese manufacturer specializing in high-quality apheresis disposables, blood bags, and related consumables.

Key Financials: 2025 Apheresis Equipment revenue US$ 80.00 Million; gross margin approximately 21.00%.
Flagship Products: Kawasumi apheresis kits, blood collection sets
2025-2026 Actions: Expanded OEM partnerships with major device vendors, optimized manufacturing efficiency, and tailored kits for regional clinical protocols.
Three-line SWOT: Reputable quality and customization capability; Limited proprietary hardware platform; Opportunity—rising procedure volumes driving recurring demand for low-cost yet reliable disposables.
Notable Customers: Japanese Red Cross centers, Asian blood banks, OEM relationships with global device manufacturers
7

Nikkiso Co., Ltd.

Technology company focused on dialysis and blood purification systems, incorporating apheresis functionalities for critical-care settings.

Key Financials: 2025 Apheresis Equipment revenue US$ 60.00 Million; segment CAGR estimated at 6.20%.
Flagship Products: Nikkiso apheresis modules, dialysis platforms
2025-2026 Actions: Piloted combined renal and apheresis therapies, expanded into high-acuity ICUs, and collaborated with clinicians on protocol standardization.
Three-line SWOT: Integration with strong dialysis portfolio; Smaller apheresis-specific brand recognition; Opportunity—adoption of multimodal extracorporeal therapies in sepsis and multi-organ failure.
Notable Customers: Asian tertiary hospitals, Middle Eastern ICU networks, selected European renal centers
8

Kaneka Corporation

Innovator in lipoprotein apheresis and immunoadsorption systems serving cardiology and autoimmune segments.

Key Financials: 2025 Apheresis Equipment revenue US$ 55.00 Million; operating margin 15.40%.
Flagship Products: Liposorber, Immusorba series
2025-2026 Actions: Expanded indications for dyslipidemia and autoimmune diseases, built clinical evidence, and supported specialized center-of-excellence programs.
Three-line SWOT: Unique focus on niche high-value indications; Limited breadth in general-purpose apheresis; Opportunity—growing awareness of lipoprotein apheresis for refractory cardiovascular risk.
Notable Customers: Specialized cardiology centers, academic hospitals, autoimmune disease clinics in Japan and Europe
9

Macopharma SA

European supplier of apheresis disposables, blood bags, and transfusion solutions for blood centers and hospitals.

Key Financials: 2025 Apheresis Equipment revenue US$ 45.00 Million; estimated EBITDA margin 13.10%.
Flagship Products: Macopharma apheresis kits, platelet collection sets
2025-2026 Actions: Targeted value-based tenders, expanded private-label partnerships, and invested in supply chain robustness for critical consumables.
Three-line SWOT: Strong ties with European blood services; Absence of proprietary hardware limits solution control; Opportunity—demand for reliable consumables in constrained public-health budgets.
Notable Customers: European national blood services, regional blood centers, Middle Eastern transfusion departments
10

Cerus Corporation

Specialty company focused on pathogen reduction for blood components, increasingly integrated into apheresis workflows.

Key Financials: 2025 Apheresis Equipment revenue US$ 40.00 Million; company R&D intensity above 20.00%.
Flagship Products: INTERCEPT Blood System
2025-2026 Actions: Integrated pathogen reduction with platelet and plasma apheresis, secured multi-country framework agreements, and advanced regulatory filings.
Three-line SWOT: Unique safety-focused technology with strong regulatory backing; Dependent on reimbursement and policy adoption; Opportunity—tightening blood safety regulations worldwide favoring pathogen reduction.
Notable Customers: American Red Cross affiliates, European blood establishments, select Asia-Pacific blood centers

SWOT Leaders

Fresenius SE & Co. KGaA (Fresenius Kabi)

SWOT Snapshot

SWOT
Strengths

Extensive global installed base, comprehensive portfolio, strong service infrastructure, and long-term plasma-center partnerships.

Weaknesses

Complex corporate structure and broad portfolio can dilute focus on breakthrough apheresis innovation and speed of execution.

Opportunities

Rising global demand for plasma-derived therapies and hospital outsourcing of service contracts for critical equipment.

Threats

Pricing pressure from competitors, tightening procurement rules, and potential disruptions in raw-material and disposable supply chains.

Haemonetics Corporation

SWOT Snapshot

SWOT
Strengths

Deep specialization in blood management, strong software and analytics stack, and high loyalty among large plasma networks.

Weaknesses

High exposure to plasma market cycles and donor-availability trends, with limited diversification across other modalities.

Opportunities

Global expansion into emerging markets and increased adoption of automation in blood centers and donation workflows.

Threats

Competitive launches of next-generation plasma systems and risk of commoditization in high-volume disposables segments.

Terumo BCT, Inc.

SWOT Snapshot

SWOT
Strengths

Strong clinical reputation in therapeutic apheresis, broad modality coverage, and integration with cell and gene therapy workflows.

Weaknesses

Complex systems requiring intensive training, potentially slowing adoption in resource-constrained hospitals and smaller centers.

Opportunities

Rapid expansion of cellular immunotherapies and demand for sophisticated apheresis platforms in oncology and transplant centers.

Threats

Emerging cell-therapy technologies, budget constraints in hospitals, and regional competitors with lower-cost alternatives.

Apheresis Equipment Market Regional Competitive Landscape

North America remains the largest and most profitable region, underpinned by dense plasma-collection networks, stringent blood safety regulations, and high hospital procedure volumes. Fresenius Kabi, Haemonetics Corporation, Terumo BCT, and Cerus dominate key accounts, while payers increasingly scrutinize cost per procedure, encouraging automation and efficiency-focused innovation among Apheresis Equipment market companies.

Europe shows steady demand driven by aging populations, neurology and autoimmune indications, and robust public blood services. Fresenius Kabi, Terumo BCT, Macopharma, and Kaneka are prominent, supported by strong distributor networks. Procurement is tender-driven, favoring Apheresis Equipment market companies that combine competitive pricing, proven clinical evidence, and reliable regional service coverage.

Asia-Pacific is the fastest-growing region, with Japan, China, India, and Southeast Asia expanding plasma collection and therapeutic apheresis capacity. Terumo BCT, Asahi Kasei Medical, Nikkiso, Kawasumi, and Fresenius Kabi gain share as governments upgrade hospital infrastructure. Local manufacturing, training, and tailored disposables offerings are central differentiators for Apheresis Equipment market companies in this region.

Latin America and the Middle East & Africa represent smaller but increasingly strategic markets, supported by donor-safety initiatives and modernization of tertiary hospitals. B. Braun, Fresenius Kabi, Macopharma, and Nikkiso leverage established critical-care and dialysis footprints. Apheresis Equipment market companies that offer flexible financing, turnkey training, and rugged systems gain advantage in budget-constrained settings.

In high-income Asia, particularly Japan and South Korea, clinical sophistication and reimbursement frameworks favor advanced therapeutic apheresis modalities. Asahi Kasei Medical, Kaneka, Nikkiso, Terumo BCT, and Kawasumi lead, with selective adsorption and lipoprotein apheresis seeing increased adoption. Collaboration with academic centers is a key strategy for Apheresis Equipment market companies seeking guideline inclusion and indication expansion.

Apheresis Equipment Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

ApherDx Analytics
Disruptor
USA

Cloud-native analytics platform that ingests real-time data from diverse apheresis devices to optimize scheduling, predict consumable demand, and reduce donor chair time.

PlasmaFlow Technologies
Disruptor
Germany

Developing compact, energy-efficient apheresis systems aimed at decentralized plasma collection in smaller clinics and mobile donation units.

NeoImmuno Filters
Disruptor
Belgium

Specialized in next-generation adsorption cartridges targeting autoimmune and inflammatory mediators, designed to retrofit major existing apheresis consoles.

AuroApher Lifesciences
Disruptor
India

Cost-optimized therapeutic apheresis platform combining robust hardware with low-cost disposables for emerging-market hospitals and regional blood centers.

SmartDonor Cloud
Disruptor
South Korea

Donor engagement and telehealth platform integrating with apheresis systems to personalize donation intervals and improve donor retention and safety.

Apheresis Equipment Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Apheresis Equipment market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Apheresis Equipmentmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.